Core Viewpoint - Anselme Limited has increased its stake in Huakang Biomedical (08622) by acquiring 138.672 million shares at an average price of HKD 0.126 per share, totaling approximately HKD 17.4727 million, resulting in a new holding of about 259 million shares, representing 51.84% ownership [1] Group 1 - Anselme Limited's acquisition of shares occurred on October 9 [1] - The average price per share for the transaction was HKD 0.126 [1] - The total amount spent on the acquisition was approximately HKD 17.4727 million [1] Group 2 - Following the transaction, Anselme Limited's total shareholding in Huakang Biomedical increased to approximately 259 million shares [1] - The new ownership percentage after the acquisition is 51.84% [1] - The transaction involved other related parties, specifically Zhou Xun Yong [1]

Core Insights - Hong Kong Stock Exchange data indicates that on October 9, Huakang Biomedical (08622) shareholders transferred stocks from Qingtian Securities to Jinlifeng Securities, with a transfer market value of HKD 54.8386 million, accounting for 27.74% of the total [1] Group 1 - On October 9, Huakang Biomedical and the offeror Anselme Limited jointly announced a sale and purchase agreement, where the seller Li Jingyang conditionally agreed to sell and the offeror conditionally agreed to acquire all legal and beneficial ownership and rights of the shares (1.387 billion shares), representing approximately 27.71% of the total issued share capital as of the announcement date, for a total consideration of HKD 17.4727 million, equivalent to HKD 0.126 per share [1]

Core Viewpoint - Huakang Biomedical (08622) announced that its shares will resume trading on October 10, 2025, at 9:00 AM [1] Company Summary - The company has made an official announcement regarding the resumption of its stock trading [1]

Group 1 - The core point of the article is the transfer of shares of Huakang Biomedical (08622) from Qingtian Securities to Jinlifeng Securities, with a market value of HKD 54.83 million, representing 27.74% of the total shares [1] - On October 9, Huakang Biomedical and the offeror Anselme Limited announced a conditional agreement for the sale of 138.7 million shares, which constitutes approximately 27.71% of the company's total issued share capital as of the announcement date [1] - The total consideration for the shares is HKD 17.47 million, equating to a price of HKD 0.126 per share [1]

Group 1 - The core point of the announcement is that Anselme Limited, as the buyer, has entered into a conditional sale agreement with seller Li Jingyang to acquire 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share [1] - Following the completion of the transaction, the buyer will directly and beneficially own 121 million shares, which is about 24.13% of the total issued share capital of the company [1] - After the completion of the transaction, the buyer, Dr. Zhou and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital [1][2] Group 2 - The offer price of HKD 0.126 per share represents a discount of approximately 68.10% compared to the closing price of HKD 0.395 per share on the date of the announcement [1] - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [3]

Group 1 - The core point of the announcement is that Anselme Limited, as the buyer, has entered into a conditional sale agreement with seller Li Jingyang to acquire 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share [1] - Following the completion of the transaction, the buyer will directly and beneficially own 121 million shares, which is about 24.13% of the total issued share capital of the company [1] - After the completion of the transaction, the buyer, Dr. Zhou and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital of the company [1] Group 2 - The buyer is wholly owned by Dr. Zhou Xun Yong, who is also the sole director of the buyer [2] - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [2]

Core Viewpoint - The announcement details a conditional sale agreement between Anselme Limited (the offeror) and Li Jingyang (the seller) for the acquisition of 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share, which is a discount of about 68.10% compared to the market price on the announcement date [1][2]. Group 1 - The offeror will acquire 138.7 million shares, representing approximately 27.71% of the total issued share capital of Huakang Biomedical [1]. - Prior to the completion of the transaction, the offeror directly and beneficially owns 121 million shares, which is about 24.13% of the total issued share capital [1]. - Following the completion of the transaction, the offeror, Dr. Zhou, and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital [1]. Group 2 - The offeror is wholly owned by Dr. Zhou Xun Yong, who is also the sole director of the offeror [2]. - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 聯 合公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔 任 何 責 任。 本 聯 合 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 華 康 生 物 醫 學 控 股 有 限 公 司 證 券 之 邀 請 或 要 約 或 構 成 其 一 部 分，或 於 任 何 司 法 權 區 招 攬 任 何 表 決 權 或 批 准，亦 不 得 在 與 適 用 法 律 法 規 相 抵 觸 之 情 況 下 於 任 何 司 法 權 區 出 售、發 行 或 轉 讓 華 康 生 物 醫 學 控 股 有 限 公 司 證 券。本 聯 合 公 告 不 會 在 構 成 違 反 有 關 司 法 權 區 相 關 法 律 的 情 況 下 於 或 向 任 何 司 法 權 區 發 佈、刊 發 或 派 發。 ANSELME LIMITED （於 英 屬 處 女 群 島 註 冊 成 立 之 有 限 公 司） HUAKANG BIOMED ...

Core Viewpoint - Huakang Biomedical (08622) has announced that its shares will be suspended from trading on the Hong Kong Stock Exchange's GEM starting from October 9, 2025, at 1 PM, pending the release of an announcement containing insider information in accordance with the Hong Kong Code on Takeovers and Mergers [1] Summary by Category - **Company Announcement** - Huakang Biomedical's shares will be suspended from trading on the Hong Kong Stock Exchange's GEM [1] - The suspension is effective from October 9, 2025, at 1 PM [1] - The suspension is due to the pending announcement of insider information [1] - **Regulatory Compliance** - The company is acting in accordance with the Hong Kong Code on Takeovers and Mergers [1]

Core Viewpoint - Huakang Biomedical (08622) has announced that its shares will be suspended from trading on the Hong Kong GEM starting from October 9, 2025, at 1:00 PM, pending the issuance of an announcement containing inside information in accordance with the Hong Kong Code on Takeovers and Mergers [1] Group 1 - The suspension of trading is a regulatory measure in response to the need for disclosure of inside information [1] - The announcement indicates potential significant developments regarding the company that may impact its stock performance [1]